FDA Clears Adjunctive AI Mapping of White Matter on Diffusion MRI
Through automated processing of diffusion-weighted magnetic resonance imaging (MRI) scans, the Advanced Neuro Diagnostic Imaging (ANDI) software performs detailed analysis of white matter microstructure.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Advanced Neuro Diagnostic Imaging (ANDI, Imeka), an artificial intelligence (AI)-enabled neuroimaging software that provides mapping of white matter microstructure on diffusion magnetic resonance imaging (MRI).
Employing a combination of modelling reconstruction algorithms, fiber bundling and tractography, the ANDI software platform assesses the microstructure of connecting white matter bundles through automated processing of diffusion-weighted MRI, according to Imeka.
The company said the ANDI software provides detailed analysis of the micro- and macrostructural values of white matter bundles and produces a subsequent DICOM-encapsulated PDF report noting white matter bundles that may have significant deviation from normative values.
“Imeka is pioneering AI in diffusion MRI-based white matter imaging to evaluate microstructural properties of white matter in greater detail than any other techniques,” noted Jean-Rene Belanger, the chief executive officer of Imeka.
Imeka added that recently announced CPT 3 codes from the American Medical Association (AMA) are geared toward quantitative brain MRI assessment and should facilitate reimbursement for use of the ANDI software.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
